Biotech News
TG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026
Seven-year BRIUMVI data demonstrate sustained disease control, with approximately 88% of participants remaining free from confirmed disability progression after 7 years of continuous treatment Phase 1 subcutaneous BRIUMVI bioavailability data support quarterly dosing schedule being evaluated in a
